Considering the effectiveness of the RAN–AMIO combination strategy and the lower incidence of proarrhythmia in experimental and clinical settings, the present findings argue for the need for an alternative treatment even in patients with a history of coronary heart disease and concomitant AT. This evidence concerns the gene RAN and ataxia telangiectasia.